聯合租賃 URI 深 滬
等待開盤 08-08 09:30:00 美东时间
854.61
-6.650
-0.77%
華盛通- 最 高872.39
- 今 開872.39
- 成交量 43.18万股
- 最 低 848.75
- 昨 收 861.26
- 總市值 555.49亿
- 52周最高 903.605
- 市盈率 靜 22.09
- 換手率 0.00%
- 52周最低 524.1236
- 委 比 95.48%
- 總股本 6499.90万
- 歷史最高 903.605
- 量 比 0.91
- 振 幅 2.74%
- 歷史最低 -3.21
- 每 手 1
- 風險率 81.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Amcor announces shortlist for latest Lift-Off competition
Four innovative start-ups selected for solutions that provide barriers for compostable substrates ZURICH, Aug. 4, 2025 /PRNewswire/ -- Amcor (NYSE: AMCR, ASX: AMC), a global leader in develo...
08-04 22:00
AIM ImmunoTech Announces Company Update Including Mid-Year Report Of Ampligen In Combination With AstraZeneca's Imfinzi For Treatment Of Pancreatic Cancer Demonstrating Signs Of Both No Significant Toxicity And Superior PFS And OS.Company Also Bolstered Cash Position To Fund Operations For ~12 Months
Primary focus on pancreatic cancerMid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates positive signs of both
08-04 21:06
SciBase Announces Outcome in Directed Share Issue
STOCKHOLM, Aug. 1, 2025 /PRNewswire/ -- On 16 June 2025, SciBase Holding AB (pu...
08-01 15:40
Why Is Micro-Cap AIM ImmunoTech Stock Surging?
AIM ImmunoTech shares rise after DURIPANC trial data show superior survival and safety in metastatic pancreatic cancer patients.
07-28 23:12
UroGen Pharma Announces Publication In Reviews In Urology Of Results From Phase 3b Study Evaluating Feasibility Of Administering ZUSDURI For Intravesical Solution In Home Setting
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty cancers, today announced the publication in Reviews in Urology of results
07-28 20:08
美股大行评级 | DA Davidson上调谷歌目标价从160美元升至180美元；波士顿科学获三家大行上调目标价
今日重点评级关注：Lake Street：维持BlackSky Technology"买入"评级，目标价从18美元升至28美元；瑞杰金融：维持SEI Investments"跑赢大市"评级，目标价从115美元升至118美元
07-25 09:35
United Rentals Raises FY2025 Sales Guidance from $15.60B-$16.10B to $15.80B-$16.10B vs $15.89B Est
United Rentals (NYSE:URI) raises FY2025 sales outlook from $15.60 billion-$16.10 billion to $15.80 billion-$16.10 billion vs $15.89 billion estimate.
07-24 04:23
United Rentals Q2 Adj. EPS $10.47 Misses $10.52 Estimate, Sales $3.94B Beat $3.90B Estimate
United Rentals (NYSE:URI) reported quarterly earnings of $10.47 per share which missed the analyst consensus estimate of $10.52 by 0.47 percent. This is a 2.15 percent decrease over earnings of $10.70 per share from the
07-24 04:23
